Human Genome Sciences Announces Process Development and Manufacturing Alliance Wi...(the uncertainty and timing ofclinical tr...)

Date:9/4/2008

the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

'/>"/>

SOURCE Human Genome Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Conference
2. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
3. UC Riverside researcher develops novel method to grow human embryonic stem cells
4. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
5. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
6. Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response
7. Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
8. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
9. Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results
10. New map IDs the core of the human brain
11. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use